Big Pharma R&D is exiting China, but leaving a legacy; China's biotech execs couldn’t be happier
→ Bloomberg posted a story about the Big Pharmas that have been bailing out of China recently. We’ve been covering this step by step at Endpoints News, but it’s worth pointing out that the big outfits that entered China with such fanfare around 7 or 8 years ago accomplished very little of note with their R&D groups. They did, however, effectively train a whole generation of execs who are playing a big role in making the Asian giant a big new player in biopharma. That may not have been the payback they were looking for, but it is significant.
→ Following up on the China story, Reuters offers this from Chi-Med’s Christian Hogg: “China is in vogue because of the positive moves on the regulatory side, as well as advances at companies. It’s a big, big change versus 10 years ago and it is accelerating.”
→ Boston-based Albireo Pharma is touting final results from its Phase II study of lead product candidate A4250 in children with cholestatic liver disease.